Caixin: Hu Xiaowei, Associated with Cambodia's Prince Group, Sanctioned by the UK
On March 29, it was reported that after more than two months of detention of Chen Zhi, the founder of Cambodia's Prince Group, the UK has further imposed sanctions on a Southeast Asian fraud network, which includes Hu Xiaowei, closely associated with Chen Zhi. The sanctions document released by the UK refers to Hu Xiaowei as 'Wu Anming,' stating that he is linked to Chen Zhi and the Prince Group, and is described as 'a long-term collaborator of Chen Zhi' who provides financial services, economic resources, and technical support. It is reported that the cryptocurrency trading platform 'New Coin' has also been sanctioned; New Coin is considered one of the largest illegal markets in Southeast Asia, providing cryptocurrency services to fraud centers, including the sale of stolen personal data and satellite internet equipment used to contact victims. (Caixin)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
